Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Premal H. Thaker, MD, MS
Advertisement
Articles by Premal H. Thaker, MD, MS
Advertisement
Latest Updated Articles
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer SubgroupPublished: June 3rd 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Adjuvant Therapy Confers Postoperative ctDNA Clearance, DFS Benefit in CRC
2
Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma
3
Temab-A Displays Early Efficacy in Locally Advanced/Metastatic PDAC
4
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm
5
